checkAd

     173  0 Kommentare INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay - Seite 3

    INmune Bio Contact:

    David Moss, CFO
    (858) 964-3720
    info@inmunenbio.com

    Lesen Sie auch

    Investor Contact:
    Jason Nelson, Core IR
    (516) 842-9614 x-823



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    INmune Bio Inc. Announces 24-Month Stability Validation of XPro for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay - Seite 3 Boca Raton, Florida, April 23, 2024 (GLOBE NEWSWIRE) -  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is …